This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Stay Ahead With 4 Healthcare Stocks Poised for Q1 Earnings Beat
by Kaibalya Pravo Dey
Growing patient volumes, advancements in technology, admissions, premium rate hikes and other factors are likely to have benefited healthcare players during Q1. Companies like CI, HCA, AVTR and THC can outperform.
Zacks.com featured highlights include Hubbel, Caterpillar, The Timken Co. and HCA Healthcare
by Zacks Equity Research
Hubbel, Caterpillar, The Timken Co. and HCA Healthcare are part of the Zacks Screen of the Week article.
Community Health Systems (CYH) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Community Health Systems (CYH) delivered earnings and revenue surprises of 26.32% and 1.49%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Scoop up These 4 GARP Stocks to Receive Handsome Returns
by Zacks Equity Research
The GARP strategy helps investors gain exposure to stocks that have impressive prospects and are trading at a discount. HUBB, CAT, TKR and HCA are some stocks that hold promise.
Why HCA Healthcare (HCA) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Earnings Growth & Price Strength Make HCA Healthcare (HCA) a Stock to Watch
by Zacks Equity Research
The Zacks Focus List offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.
Insulet (PODD) Awaits Q1 Earnings Release: Here's What to Expect
by Zacks Equity Research
Strong global new customer starts fueled by the ongoing Omnipod 5 demand are expected to significantly benefit Insulet's (PODD) first-quarter performance.
Can Higher Visits Soften Cost Blow for Teladoc (TDOC) in Q1?
by Zacks Equity Research
Teladoc's (TDOC) first-quarter results are expected to have benefited from higher visits. However, high costs might have partially offset the positives.
Tenet Healthcare (THC) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Tenet (THC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is It Worth Investing in HCA (HCA) Based on Wall Street's Bullish Views?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in HCA (HCA). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Ahead of HCA (HCA) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics
by Zacks Equity Research
Get a deeper insight into the potential performance of HCA (HCA) for the quarter ended March 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Should You Buy HCA Healthcare (HCA) Ahead of Q1 Earnings?
by Zacks Equity Research
HCA Healthcare's (HCA) first-quarter results are likely to reflect increased admissions and patient days.
Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Why HCA Healthcare (HCA) Outpaced the Stock Market Today
by Zacks Equity Research
In the closing of the recent trading day, HCA Healthcare (HCA) stood at $310.31, denoting a +1.7% change from the preceding trading day.
Should You Buy Encompass Health (EHC) Ahead of Q1 Earnings?
by Zacks Equity Research
Encompass Health's (EHC) Q1 results are likely to benefit on the back of growing patient volumes and commendable expansion initiatives.
Will Acute Care Unit Aid Universal Health's (UHS) Q1 Earnings?
by Zacks Equity Research
Universal Health's (UHS) Q1 results are expected to be aided by growing patient volumes and surgical cases, partly offset by increased expenses.
HCA Healthcare (HCA) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
HCA (HCA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
5 Large-Cap Medical Stocks to Buy Ahead of Q1 Earnings
by Nalak Das
We have narrowed our search to five S&P 500 medical stocks that are poised to beat on first-quarter earnings results.These are: HCA, UHS, LH, EW, PODD.
Here's Why HCA Healthcare (HCA) Fell More Than Broader Market
by Zacks Equity Research
In the latest trading session, HCA Healthcare (HCA) closed at $311.03, marking a -0.91% move from the previous day.
Are Medical Stocks Lagging HCA Healthcare (HCA) This Year?
by Zacks Equity Research
Here is how HCA Healthcare (HCA) and Addus HomeCare (ADUS) have performed compared to their sector so far this year.
Here's Why HCA Healthcare (HCA) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
5 Safe Stocks to Buy as Severe Volatility Grips Wall Street
by Nalak Das
We have narrowed our search to five stocks from defensive sectors to safeguard one's portfolio. These are: AWK, ATO, CELH, HCA, TAP.
HCA Healthcare (HCA) Stock Declines While Market Improves: Some Information for Investors
by Zacks Equity Research
In the latest trading session, HCA Healthcare (HCA) closed at $327.25, marking a -0.16% move from the previous day.
4 Sector ETFs & Stocks to Benefit From Hot Inflation
by Sanghamitra Saha
U.S. inflation jumped in March, surpassing expectations primarily due to higher petrol and shelter costs, dashing hopes of a June interest rate cut by the Fed.
Market Jitters: 2 Top Ranked Stocks for Defensive Positioning
by Ethan Feller
With the jump in inflation and rise in interest rate uncertainty investors may want to consider defensive stocks